Company |
Company |
Value (M) |
Type/product area |
Terms/details |
Date |
APRIL | |||||
Amneal Pharmaceuticals LLC (Bridgewater, N.J.) |
Actavis Australia Pty Ltd. (subsidiary of Actavis plc; Dublin) |
ND |
Agreement for a binding letter of intent for Amneal to acquire the Australian generic pharmaceutical business division |
Financial terms were not disclosed |
4/1/15 |
Astellas Pharma Inc. (Tokyo) |
Ventana Medical Systems Inc. (Tucson, Ariz.; unit of the Roche Group) |
ND |
Master collaboration agreement to develop automated tissue diagnostics in support of therapeutic compounds in development |
Initial projects will support early clinical trials for Astellas' ASP5878; Ventana will develop an immunohistochemistry test identifying FGF19 in certain solid tumors |
4/15/15 |
Chemrar High Tech Center (Moscow) |
Lancet Russian Distribution Co. |
ND |
Collaboration for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry |
Chemrar and Lancet plan to develop and manufacture new drugs in major therapeutic areas that are a high priority for the Russian Federation health care system |
4/17/15 |
Eli Lilly and Co. (Indianapolis) |
Bristol-Myers Squibb Co. (New York) |
ND |
Agreement to transfer rights to Erbitux (cetuximab) in North America, including the U.S., Canada and Puerto Rico, from BMS to Lilly |
The move comes after a 14-year collaboration, which includes Lilly's wholly owned subsidiary, Imclone LLC; BMS will receive tiered royalties based on net product sales in North America after the completion of the transition through September 2018 |
4/17/15 |
Merck KGaA (Darmstadt, Germany) |
Pfizer Inc. (New York) |
ND |
Agreement allowing the companies to co-promote Pfizer's anaplastic lymphoma kinase inhibitor Xalkori (crizotinib) in an effort to establish a sales force in advance of the potential launch of avelumab |
Xalkori will be co-promoted in two waves, first in the second and third quarters of 2015 in the U.S., Canada, Japan and five European Union countries, then in 2016 in China and Turkey; Merck will receive a reimbursement for promotion of Xalkori this year, after which the companies will split profits, with 80% accruing to Pfizer and 20% going to Merck starting in 2016 |
4/8/15 |
Mylan NV (Potters Bar, UK; a unit of Mylan Inc.) |
Perrigo Co. plc (Dublin) |
ND |
Mylan made a nonbinding proposal to acquire Perrigo for $205 in a combination of cash and Mylan stock for each Perrigo share |
Perrigo shareholders will receive $60 in cash and 2.2 Mylan ordinary shares for each Perrigo ordinary share; if completed, Mylan shareholders would own about 61.8%; Perrigo rejected a revised offer of $75 per share in cash and 2.3 Mylan ordinary shares |
4/27/15 |
UCB SA (Brussels) |
Dr. Reddy's Laboratories Ltd. (Hyderabad, India) |
ND |
Agreement to acquire a select portfolio of the established products business of UCB in the territories of India, Nepal, Sri Lanka and Maldives |
The acquired business is being sold on a slump sale basis; the transaction includes approximately 350 employees engaged in operations of the India business |
4/2/15 |
MAY | |||||
Aeterna Zentaris Inc. (Quebec City) |
EMD Serono Inc. (Rockland, Mass.) |
ND |
Promotional services agreement that will allow Aeterna to promote Saizen in the U.S. |
Saizen is used to treat growth hormone deficiency in children and adults |
5/8/15 |
AM-Pharma NV (Bunnik, the Netherlands) |
Pfizer Inc. (New York) |
$600 |
Pfizer intends to acquire AM-Pharma for $600M |
The transaction includes $87.5M up front and $512.5M from the exercise of the option, pending positive results from an ongoing phase II trial of human recombinant alkaline phosphatase in acute kidney injury, and subsequent milestones; the product must get to market for the full $600M |
5/12/15 |
Ani Pharmaceuticals Inc. (Baudette, Minn.) |
Teva Pharmaceuticals Industries Ltd. (Jerusalem) |
$5 |
Ani acquired the approved new drug application for a testosterone gel 1% product previously licensed to Teva |
Ani will pay Teva up to $5M at a rate of 5% of commercial sales of the product |
5/14/15 |
Baxter International Inc. (Deerfield, Ill.) |
Sigma-Tau Finanziaria SpA (Rome) |
$900 |
Agreement for Baxter to acquire the Oncaspar (pegaspargase) product portfolio |
Baxter will pay $900M through a combination of foreign cash and debt; Oncaspar is used to treat acute lymphoblastic leukemia and has about $100M in annual sales; the deal includes a new chemical entity, calaspargase pegol, and Oncaspar will be tested for potential new indications; the assets will fall under Baxter's new business unit, Baxalta Inc. |
5/13/15 |
OSE Pharma SA (Paris) |
Rafa Laboratories Ltd. (Jerusalem) |
ND |
Exclusive long-term agreement for the registration, marketing, distribution and sale of Tedopi, which combines 10 neo-epitopes directed against five tumor-associated antigens |
The product is about to enter a pivotal phase III study in patients with advanced non-small-cell lung cancer who express HLA-A2 and failed first-line therapy; Rafa will submit the drug for approval in Israel, market and distribute it, and will pay an up-front fee and milestone payments, equally sharing profits |
5/14/15 |
|
Notes The date indicated refers to the BioWorld Today issue in which the news item can be found. For more information about individual companies and/or products, see Thomson Reuters Cortellis. | |||||